Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models

  title={Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models},
  author={Claire J. Foldi and Paul Liknaitzky and Martin Williams and Brian J. Oldfield},
  journal={Frontiers in Neuroscience},
Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the potential for classical psychedelics, including psilocybin, to alleviate symptoms of AN that relate to… 

Figures from this paper

From Psychiatry to Neurology: Psychedelics as Prospective Therapeutics for Neurodegenerative Disorders.
Recent findings and information on how psychedelics may act therapeutically on cells within the Central Nervous System (CNS) during brain injuries and neurodegenerative diseases are discussed.
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
It is suggested that classic psychedelics, particularly psilocybin, have the potential to normalise dysfunctional neurobiological systems in AN and provide a novel treatment intervention that is worthy of consideration, particularly for treatment-resistant patients.
Psychedelic Cognition—The Unreached Frontier of Psychedelic Science
Psychedelic compounds hold the promise of changing the face of neuroscience and psychiatry as we know it. There have been numerous proposals to use them to treat a range of neuropsychiatric
Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
The results of this pilot study will not only shed light on the acceptability, brain mechanisms, and impression of the potential efficacy of psilocybin as an adjunct treatment for AN but will be essential in shaping a subsequent Randomised Control Trial (RCT) that would test this treatment against a suitable control condition.
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
This work aims to be a reference for psychiatrists who may soon be faced with the possibility of prescribing psychedelic compounds as medications, helping them assess which compound(s) and regimen could be most useful for decreasing specific psychiatric symptoms.
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective
Pre-clinical and clinical evidence of the acute and sustained therapeutic potential of psychedelic therapy in the context of a transdiagnostic dimensional systems framework is reviewed, focusing on the Research Domain Criteria (RDoC) as a template, to assist the field in moving toward a mechanistic understanding of how psychedelics work for patients.
Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors
A framework to understand the basis for psilocybin use in individuals who are at risk of suicidal behaviors is presented and calls for clinical studies are called for.
Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy
Mindfulness-based interventions and psychedelic-assisted therapy have been experimentally utilised in recent years as alternative treatments for various psychopathologies with moderate to great success and synergistic effects when both are used in combination, in the form of potentiated therapeutic benefit are demonstrated.
Psychedelic‐assisted therapy for functional neurological disorders: A theoretical framework and review of prior reports
There is intriguing preliminary evidence to support the use of psychedelic‐assisted therapy in a growing number of psychiatric illnesses, including FNDs, as indicated by several recent neuroimaging studies on psychedelics and FNDS.
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review
Systematic reviews and meta-analyses provide support for robust, rapid and transient antidepressant and anti-suicidal effects of ketamine in treating mental health disorders.


Psychedelics and the essential importance of context
This article highlights the pharmacological mechanisms of classic psychedelics that it is believed render their effects exceptionally sensitive to context, and develops an evidence base for long-held assumptions about the critical importance of context in relation to psychedelic use that can help minimise harms and maximise potential benefits.
Eating Disorders and Hyperactivity: A Psychobiological Perspective
  • C. Davis
  • Psychology, Medicine
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 1997
The emerging picture is that psychosocial factors seem to provide the most compelling factors in the etiology and onset of the disorder, while biological factors—in most cases induced by severe malnutrition and strenuous overexercising—predominate in the maintenance of the Disorder.
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Mental disorders are rising while development of novel psychiatric medications is declining. This stall in innovation has also been linked with intense debates on the current diagnostics and
  • D. Nichols
  • Psychology, Biology
    Pharmacological Reviews
  • 2016
Blood oxygen level–dependent functional magnetic resonance imaging and magnetoencephalography have been employed for in vivo brain imaging in humans after administration of a psychedelic, and results indicate that intravenously administered psilocybin and LSD produce decreases in oscillatory power in areas of the brain’s default mode network.
Effect of Hallucinogens on Unconditioned Behavior.
This chapter focuses on three animal models that are frequently used to test the effects of hallucinogens on unconditioned behavior: head twitch response (HTR), prepulse inhibition of startle (PPI), and exploratory behavior.
Clinical potential of psilocybin as a treatment for mental health conditions.
An in-depth review of the study design and results of psilocybin use in each of the mental health disease states and symptoms and discusses the clinical potential for use is provided.